The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?
The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
A product sale nets the Australian company some much-needed cash, but its plan for the future is highly questionable.
Portico hits noninferiority, but safety looks doubtful. Abbott might want to prioritise a different approach.
Intuitive Surgical makes the most money per employee – but the title of “most improved” goes to Philips.
The overall rate of device approvals in 2019 is holding steady on last year – but the types of approvals are different.
The medtech market’s fast growth and unfettered demand attracts investment groups, while hospital suppliers consolidate.
The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.
A poor quarter is followed by an acquisition, but is it big enough?